Chromocell Therapeutics C... (CHRO)
2.68
-0.02 (-0.74%)
At close: Jan 23, 2025, 3:59 PM
2.86
6.70%
After-hours Jan 23, 2025, 07:38 PM EST
Company Description
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain.
The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family.
Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain.
Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Chromocell Therapeutics Corporation
| Country | United States |
| IPO Date | Feb 16, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Francis Knuettel II, M.B.A. |
Contact Details
Address: 4400 Route 9 South Freehold, New Jersey United States | |
| Website | https://chromocell.com |
Stock Details
| Ticker Symbol | CHRO |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001386026 |
| CUSIP Number | n/a |
| ISIN Number | US1711261057 |
| Employer ID | 20-8881686 |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| Francis Knuettel II, M.B.A. | President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary & Director |
| Dr. Eric Lang M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 15, 2025 | SCHEDULE 13G | Filing |
| Dec 11, 2024 | POS AM | Filing |
| Nov 22, 2024 | POS AM | Filing |
| Nov 22, 2024 | POS AM | Filing |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 8-K12G3 | Filing |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 4 | Filing |
| Nov 15, 2024 | 4 | Filing |
| Nov 15, 2024 | 4 | Filing |